|
1) Ober C, Hoffjan S. Asthma genetics 2006: the long and winding road to gene discovery. Genes Immun. 2006; 7: 95-100
|
|
|
|
2) Van Eerdewegh P, Little RD, Dupuis J, et al. Association of the ADAM33 gene with asthma and bronchial hyperresponsiveness. Nature. 2002; 418: 426-30
|
|
|
|
|
|
3) Noguchi E, Yokouchi Y, Zhang J, et al. Positional identification of an asthma susceptibility gene on human chromosome 5q33. Am J Respir Crit Care Med. 2005; 172: 183-8
|
|
|
|
|
|
4) Nicolae D, Cox NJ, Lester LA, et al. Fine mapping and positional candidate studies identify HLA-G as an asthma susceptibility gene on chromosome 6p21. Am J Hum Genet. 2005; 76: 349-57
|
|
|
|
|
|
5) Blakey J, Halapi E, Bjornsdottir US, et al. Contribution of ADAM33 polymorphisms to the population risk of asthma. Thorax. 2005; 60: 274-6
|
|
|
|
|
|
6) Sakagami T, Jinnai N, Nakajima T, et al. ADAM33 polymorphisms are associated with aspirin-intolerant asthma in the Japanese population. J Hum Genet. 2007; 52: 66-72
|
|
|
|
|
7) Hirota T, Hasegawa K, Obara, K, et al. Association between ADAM33 polymorphisms and adult asthma in the Japanese population. Clin Exp Allergy. 2006; 36: 884-91
|
|
|
|
|
|
8) Noguchi E, Ohtsuki Y, Tokunaga K, et al. ADAM33 polymorphisms are associated with asthma susceptibility in a Japanese population. Clin Exp Allergy. 2006; 36: 602-8
|
|
|
|
|
|
9) Lee JY, Park SW, Chang HK, et al. A disintegrin and metalloproteinase 33 protein in patients with asthma: Relevance to airflow limitation. Am J Respir Crit Care Med. 2006; 173: 729-35
|
|
|
|
|
|
10) Foley SC, Mogas AK, Olivenstein R, et al. Increased expression of ADAM33 and ADAM8 with disease progression in asthma. J Allergy Clin Immunol. 2007; 119: 863-71
|
|
|
|
|
|
11) van Diemen CC, Postma DS, Vonk JM, et al. A disintegrin and metalloprotease 33 poly-morphisms and lung function decline in the general population. Am J Respir Crit Care Med. 2005; 172: 329-33
|
|
|
|
|
|
12) Maeda Y, Hizawa N, Jinushi E, et al. Polymorphisms in the muscarinic receptor 1 gene confer susceptibility to asthma in Japanese subjects. Am J Respir Crit Care Med. 2006; 174: 1119-24
|
|
|
|
|
|
13) Palmer CN, Irvine AD, Terron-Kwiatkowski A, et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet. 2006; 38: 441-6
|
|
|
|
|
|
14) Nomura T, Sandilands A, Akiyama M, et al. Unique mutations in the filaggrin gene in Japanese patients with ichthyosis vulgaris and atopic dermatitis. J Allergy Clin Immunol. 2007; 119: 434-40
|
|
|
|
|
|
15) Palmer CN, Ismail T, Lee SP, et al. Filaggrin null mutations are associated with increased asthma severity in children and young adults. J Allergy Clin Immunol. 2007; 120: 64-8
|
|
|
|
|
|
16) Hudson TJ. Skin barrier function and allergic risk. Nature Genet. 2006; 38: 399-400
|
|
|
|
|
|
17) Nelson HS, Weiss ST, Bleecker ER, et al. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest. 2006; 129: 15-26
|
|
|
|
|
|
18) Wechsler ME, Lehman E, Lazarus SC, et al. beta-Adrenergic receptor polymorphisms and response to salmeterol. Am J Respir Crit Care Med. 2006; 173: 519-26
|
|
|
|
|
|
19) Israel E, Chinchilli VM, Ford JG, et al. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet. 2004; 364: 1505-12
|
|
|
|
|
|
20) Munakata M, Harada Y, Ishida T, et al. Molecular-based haplotype analysis of the beta 2-adrenergic receptor gene (ADRB2) in Japanese asthmatic and non-asthmatic subjects. Allergol Int. 2006; 55: 191-8
|
|
|
|